Business

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Media ReleaseCOPENHAGEN, Denmark; January 07, 2026 Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients Genmab A/S (Nasdaq: GMAB) announced today a partnership with Anthropic to advance and enhance the company’s research and development (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will design and de

articleGenmab A/sJanuary 7, 20263/company/genmab-as-1/news/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

About this update from Genmab A/s

[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"Media ReleaseCOPENHAGEN, Denmark; January 07, 2026","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":159,"olType":false},{"type":"text","content":"Genmab A/S (Nasdaq: GMAB) announced today a partnership with Anthropic to advance and enhance the company’s research and development (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities.","length":232,"tagName":"p"},{"type":"text","content":"Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab's clinical development priorities. Genmab's teams will use Claude to accelerate data processing, analysis, and document generation within defined guardrails and with human oversight to streamline complex operational activities, enhance agility, and improve consistency in supporting Genmab’s clinical programs as they progress toward key regulatory milestones.","length":495,"tagName":"p"},{"type":"text","content":""This partnership represents a step forward in Genmab’s transformation toward a more scalable, efficient, and digitally enabled R&D engine aligned with the company’s AI strategy,” said Tahamtan Ahmadi, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab. "By reducing manual burden and enabling greater scale across our operations, our partnership with Anthropic will empower our teams to focus more time on high-value scientific and strategic work, with the goal of accelerating our path to patient impact."","length":579,"tagName...

More updates from Genmab A/s

AnthropicGenmabresearch and developmentclinical development